KLS-13019
KLS-13019 is an orally active GPR55 receptor antagonist and a structural analogue of cannabidiol (CBD) . It can prevent and reverse chemotherapy-induced peripheral neuropathy (CIPN) in a dose-dependent manner in rats[1].
Product Specifications
CAS Number
1801243-39-9
UNSPSC
12352005
Target
GPR55
Type
Reference compound
Related Pathways
GPCR/G Protein; Neuronal Signaling
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/kls-13019.html
Smiles
CC([C@@H]1CCC(C)=C[C@H]1C2=C(C=C(C=C2O)CC3CN(C3)C(C)=O)O)=C
Molecular Formula
C22H29NO3
Molecular Weight
355.47
References & Citations
[1]Ippolito MJ, et al. KLS-13019, a novel structural analogue of cannabidiol (CBD) and GPR55receptor antagonist, Prevents and Reverses Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Rats. J Pharmacol Exp Ther. 2024 Aug 22:JPET-AR-2024-002190.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
56132151 3x 1.0 µg DNA
CYP17A1OS CRISPR All-in-one AAV vector set (with saCas9)(Human)
Sign In for Pricing
View Details